High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
暂无分享,去创建一个
V. Sondak | J. Kirkwood | T. Smith | M. Ernstoff | U. Rao | J. Richards | M S Ernstoff | J M Kirkwood | T J Smith | R H Blum | L. Flaherty | R. Blum | L E Flaherty | V K Sondak | J G Ibrahim | J Richards | U Rao | M Steele | J. Ibrahim | M. Steele
[1] C. Balch,et al. A Multifactorial Analysis of Melanoma: Prognostic Histopathological Features Comparing Clark's and Breslow's Staging Methods , 1978, Annals of surgery.
[2] C. Balch,et al. A Multifactorial Analysis of Melanoma: III. Prognostic Factors in Melanoma Patients with Lymph Node Metastases (Stage II) , 1981, Annals of surgery.
[3] C. Balch,et al. A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (Stage I) Melanoma Treated in Alabama, USA, and New South Wales, Australia , 1982, Annals of surgery.
[4] A. Halpern,et al. Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.
[5] N. Cascinelli. Evaluation of efficacy of adjuvant rIFN-alfa-2a in melanoma patients with regional nodal metastases (abstract) , 1995 .
[6] J. Kugler,et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Kirkwood,et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Gelber,et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J G Ibrahim,et al. The Large Sample Distribution of the Weighted Log Rank Statistic Under General Local Alternatives , 1997, Lifetime data analysis.
[10] M. Ross,et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Atkins,et al. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Binder,et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Chastang,et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases , 1998, The Lancet.